NEW YORK--(BUSINESS WIRE)--Fitch Ratings has assigned a 'AA-' rating to approximately $195 million of series 2016A revenue bonds expected to be issued by the Illinois Finance Authority (the authority) on behalf of Carle Foundation (Carle).
In addition, Carle expects to issue $50 million of series 2016B taxable variable rate demand bonds. Proceeds from the series 2016 financing will be used to finance construction of new facilities, refund Carle's series 2009D variable rate demand revenue bonds and pay the costs of issuance. The series 2016A bonds will be issued as long-term fixed rate obligations and are expected to sell via negotiated sale the week of Oct. 24.
In addition, Fitch has affirmed the 'AA-' long-term rating on the following revenue bonds issued by the authority on behalf of Carle:
--$234.7 million series 2011A;
--$7.9 million series 2009A;
--$160 million series 2009B-E*.
*Underlying rating. The bonds are supported by bank letters-of-credit issued by The Northern Trust Company or JP Morgan Chase Bank, N.A.
The Rating Outlook is Stable.
Debt payments secured by a security interest in the gross receipts of the Obligated Group (OG; which includes the Carle Foundation, the Carle Foundation Hospital, Carle Health Care, Inc. and Carle Retirement Centers, Inc.). There is no mortgage or property pledge or debt service reserve fund. The OG represents approximately 48% of total system revenues and 77% of total system assets.
KEY RATING DRIVERS
FINANCIALLY STRONG, INTEGRATED SYSTEM: Fitch views as a credit strength Carle's fully integrated clinical model that includes a tertiary hospital, a large base of employed physicians, and a health plan. Despite recent softening in operating profitability due to losses within the health plan, unrestricted liquidity at June 30th remains solid at approximately $1.2 billion equating to 159% of pro forma debt.
MANAGEABLE PRO FORMA DEBT BURDEN: Pro forma debt metrics, including the impact of the 2016 borrowing, are supportive of the rating. Pro forma MADS to total revenues of 1.7% compares favorably to the 'AA' category median of 2.2% for the six-month 2016 interim period. Despite compressed profitability in fiscal 2015 and through the six-month interim period, historical coverage of pro forma MADS of 4.6x and 4.1x, respectively, is adequate given Carle's market position and integrated delivery model.
LEADING MARKET SHARE: Carle has further extended its leading inpatient market share position to 46.8% in 2016 from 46.3% in 2015 in its primary service area of Champaign-Urbana. Carle's market share has grown every year since 2002. In addition, most of Carle's patient volume numbers continue to show growth.
CONTINUED CAPITAL SPENDING: Fitch expects capital expenditures to remain above 1x depreciation, as Carle continues to execute on its five-year capital plan. Favorably, the majority of planned projects are expected to be revenue-enhancing and no additional debt is currently planned, apart from the series 2016 borrowing.
CONTINUED STRENGTH IN PERFORMANCE: Fitch expects operating performance at the Health Alliance Medical Plan (HAMP) to improve with the decision to exit the Managed Medicaid business by the end of 2016. The improvement in insurance operations combined with steady operating performance at the Carle Foundation hospitals should allow the system to move back towards financial performance more consistent with historical results.
Located in Urbana, IL, Carle Foundation consists of 393-bed Carle Foundation Hospital, Carle Health Care, Incorporated (which includes Carle Physician Group, comprised mostly of former Clinic physicians), Carle Retirement Centers, a 174-unit retirement center d/b/a The Windsor, and a health plan.
Fitch's credit analysis is based on the results of the consolidated entity, which includes Health Alliance Medical Plans, Inc. (HAMP), a non-obligated health insurer licensed in the State of Illinois. In fiscal 2016, HAMP accounted for roughly 69% of the $2.5 billion in consolidated operating revenues.
SOLID CREDIT PROFILE
The 'AA-' rating reflects the strategic benefit of Carle's integrated delivery model, its growing market share position and its stable financial profile over the last few years.
In 2015, on a fully consolidated basis, Carle generated income from operations of $32.7 million on total revenues of $2.5 billion (1.3% margin). Through the six months ended June 30, 2016, Carle generated operating income of $26.5 million on revenues of $1.3 billion, improving operating margin to 2.1%.
On an OG-only basis, Carle generated an operating margin of 6.83% in 2015 and 9.51% in the six-month interim period.
Though solid, consolidated operating margins in both fiscal 2015 and the six-month interim period of 2016 were weaker than the 5% operating margin Carle posted in fiscal 2014. Additionally, days cash on hand slipped to 173.4 for the six months ended June 30, 2016 from 194.8 in fiscal 2015 and 231.3 in fiscal 2014. The biggest source of weakness in these two ratios came from HAMP, which is experiencing compressed operations due mainly to delayed payments from the State of Illinois, which remains without a budget. Approximately 47% of HAMP's premium revenues come from state insurance contracts.
Management has taken proactive steps to counteract the effects of these delayed payments and shore up its operations and liquidity position. To bolster its operating margin, Carle plans to exit its Managed Medicaid business by January 2017. Carle also continues to sell its state receivables aged 90 days or more to continue to grow its liquidity position. Fitch therefore expects liquidity and profitability to improve.
At June 30, 2016, Carle had unrestricted cash and investments of approximately $1.2 billion, up from just under $1.1 billion at year-end 2013. Cushion ratio of 26.6% as of June 30, 2016 compares favorably to Fitch's 'AA'-rated median. Current cash-to-debt is also a comfortable 215.7% as of the six-month interim, but this ratio declines to 159.2% when the new money debt is factored in. The strong overall growth in unrestricted cash and investments helps offset concerns about the state of Illinois' delayed payments to HAMP.
SOLID MARKET POSITION
Carle has further increased its leading inpatient market share in its primary service area of Champaign County over the last six years to 46.8% in 2016 from 39.1% in 2010. Presence Covenant has the second-largest market share position at 16.7%, and that has fallen from 20.1% in 2010.
Carle remains the market leader in key clinical lines, such as neurosciences, heart and vascular, oncology and women's services. Regionally, Carle continues to extend its reach through growth of clinical alignments with smaller, regional hospitals and expanding outpatient sites. HAMP also has a strong regional presence, and Carle and HAMP continue to explore regional business opportunities, as well as other potential initiatives around health care reform, including its ability to manage care coordination and control costs. HAMP has expanded into Washington State and Iowa, as well.
Collective proceeds from both a portion of the series 2016A bonds and a portion of the series 2016B taxable bonds will be used to finance construction of several projects that Carle identified in its five-year capital improvement plan. Major projects include a sports and orthopedic medicine center, expansion to administrative spaces for both Carle and HAMP, as well as clinical expansions at various sites. Total project costs are estimated at $200 million and will be entirely funded from the proceeds of the 2016 borrowings.
Including the net new money debt from the 2016 borrowings, Carle's pro forma long-term debt will total approximately $715 million. Following these transactions, Carle will have approximately 61% of fixed-rate debt and 39% variable rate debt. Of the variable-rate debt, approximately $160 million is letter of credit (LOC) supported and the remaining is bank loans. Expiration dates on the LOC's and bank loans range from 2019 to 2024, with no more than two expiring on any one date.
Carle has four swaps in place - two fixed payor swaps and two basis swaps. Total notional value of the swaps is $192 million. There are four counterparties, which provides for good counterparty diversity as it limits exposure to any single counterparty. The collateral thresholds on the swaps range from $15 million to $20 million and Carle has never had to post collateral. The mark-to-market on the swaps is negative $22.1 million at June 30, 2016.
Pro forma leverage metrics have moderated over the historical period and are manageable at the current rating level. Following the 2016 transactions, MADS will increase from $38 million to $43 million. In the six-month interim, pro forma MADS coverage was a solid 4.1x.
Carle covenants to disclose annual financial information within 150 days of each fiscal year-end and quarterly information within 50 days of each fiscal quarter-end to EMMA. Disclosure to date has been excellent and includes both consolidated and consolidating balance sheet, income statement and statement of cash flows, as well as management discussion and analysis.
Additional information is available at 'www.fitchratings.com'.
Revenue-Supported Rating Criteria (pub. 16 Jun 2014)
U.S. Nonprofit Hospitals and Health Systems Rating Criteria (pub. 09 Jun 2015)
Dodd-Frank Rating Information Disclosure Form
Copyright (c) 2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third- party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed.
The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.
For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001